SEOM guidelines for endometrial cancer.
Endometrial cancer (EC) is the most common gynaecological tumour in developing countries. Most patients with EC are diagnosed at an early stage with a low risk of relapse and overall survival at 5 years greater than 85%. Nevertheless, there is a subgroup of patients with a very poor prognosis due to the pathological features and molecular characteristics. Until now there has been no consensus regarding adjuvant treatment in EC patients, with many open questions: In which patients is it indicated? Which is the best approach: chemotherapy, radiotherapy or both? What is the right timing? Relevant clinical trials are in progress in order to answer these questions. Unfortunately, the survival of patients with metastatic or recurrent EC is quite short due to the poor responses to standard first-line chemotherapy and the lack of second lines of treatment.
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. amoaknin@vhebron.net
Ana
A
Oaknin
Víctor
V
Rodríguez-Freixinós
Isabela
I
Díaz de Corcuera
Fernando
F
Rivera
José María
JM
del Campo
D018269:Carcinoma, Endometrioid / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008495:Medical Oncology / Q000331:legislation & jurisprudence / Q000458:organization & administration; D009362:Neoplasm Metastasis; D011379:Prognosis; D012008:Recurrence; D012955:Societies, Medical / Q000331:legislation & jurisprudence / Q000458:organization & administration; D013030:Spain